Identification of human UGT2B7 as the major isoform involved in the O-glucuronidation of chloramphenicol

Drug Metabolism and Disposition

Volumn 38, Issue 3, 2010, Pages 368-375

  Chen, Mei ^a   LeDuc, Barbara ^a   Kerr, Stephen ^a   Howe, David ^b   Williams, David A ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCURONIDASE; CHLORAMPHENICOL; GLUCURONIDE; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; HYODEOXYCHOLIC ACID; PROPOFOL; SEROTONIN; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; DRUG GLUCURONIDATION; ENZYME ACTIVITY; ENZYME KINETICS; HUMAN; HYDROLYSIS; INHIBITION KINETICS; LIVER MICROSOME; MICHAELIS MENTEN KINETICS; PHENOTYPE; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; CHLORAMPHENICOL; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; ISOENZYMES; KINETICS; METABOLIC DETOXICATION, PHASE II; MICROSOMES, LIVER; RECOMBINANT PROTEINS; STATISTICS, NONPARAMETRIC; SUBSTRATE SPECIFICITY; ZIDOVUDINE;

EID: 76749099832     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.029900     Document Type: Article

References (32)

1. Barre L, Fournel-Gigleux S, Finel M, Netter P, Magdalou J, and Ouzzine M (2007) Substrate specificity of the human UDP-glucuronosyltransferase UGT2B4 and UGT2B7. Identification of a critical aromatic amino acid residue at position 33. FEBS J 274:1256-1264.
2. Bhasker CR, McKinnon W, Stone A, Lo AC, Kubota T, Ishizaki T, and Miners JO (2000) Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharamacogenetics 10:679-685.
3. Boucher FD, Modlin JF, Weller S, Ruff A, Mirochnick M, Pelton S, Wilfert C, McKinney R Jr, Crain MJ, and Elkins MM (1993) Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr 122:137-144.
4. Bouwmeester NJ, Hop WC, van Dijk M, Anand KJ, van den Anker JN, and Tibboel D (2003) Postoperative pain in the neonate: age-related differences in morphine requirements and metabolism. Intensive Care Med 29:2009-2015.
5. Brook I (2004) Management of anaerobic infection. Expert Rev Anti Infect Ther 2:153-158.
6. Chen M, Howe D, Leduc B, Kerr S, and Williams DA (2007) Identification and characterization of two CP glucuronides from the in vitro glucuronidation of CP in human liver microsomes. Xenobiotica 37:954-971.
7. Coffman BL, King CD, Rios GR, and Tephly TR (1998) The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 26:73-77.
8. Court MH, Duan SX, von Moltke LL, Greenblatt DJ, Patten CJ, Miners JO, and Mackenzie PI (2001) Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther 299:998-1006.
9. Court MH, Krishnaswamy S, Hao Q, Duan SX, Patten CJ, Von Moltke LL, and Greenblatt DJ (2003) Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 31:1125-1133.
10. Court MH (2005) Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Methods Enzymol 400:104-116.
11. Glazko AJ, Dill WA, and Rebstock MC (1950) Biochemical studies on chloramphenical (chloromycetin). III. Isolation and identification of metabolic products in urine. J Biol Chem 183:679-691.
12. Glazko AJ (1966) Identification of CP metabolites and some factors affecting metabolic disposition. Antimicrob Agents Chemother 6:655-665.
13. Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254.
14. Hutzler JM and Tracy TS (2002) Atypical kinetic profiles in drug metabolism reactions. Drug Metab Dispos 30:355-362.
15. Kauffman RE, Thirumoorthi MC, Buckley JA, Aravind MK, and Dajani AS (1981) Relative bioavailability of intravenous chloramphenicol succinate and oral chloramphenicol palmitate in infants and children. J Pediatr 99:963-967.
16. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, and Kauffman RE (2003) Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 349:1157-1167.
17. Krishnaswamy S, Duan SX, Von Moltke LL, Greenblatt DJ, Sudmeier JL, Bachovchin WW, and Court MH (2003) Serotonin (5-hydroxytryptamine) glucuronidation in vitro: assay development, human liver microsome activities and species differences. Xenobiotica 33:169-180.
18. Lambdin MA, Waddell WW Jr, and Birdsong M (1960) CP toxicity in the premature infant. Pediatrics 25:935-940.
19. Miles MV (1983) Pediatric pharmacokinetics, in Applied Clinical Pharmacokinetics (Mungall DR ed), pp 367-388, Raven Press, New York.
20. Miners JO, Smith PA, Sorich MJ, McKinnon RA, and Mackenzie PI (2004) Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol 44:1-25.
21. Miners JO, Knights KM, Houston JB, and Mackenzie PI (2006) , In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 71:1531-1539.
22. National Toxicology Program (2002) Chloramphenicol. Rep Carcinog 10:48-50.
23. Ogilvie BW, Usuki E, Burton A, Yerino P, and Parkinson A (2008) In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs (reaction phenotyping) with emphasis on cytochrome P450, in Drug-Drug Interactions. 2nd ed (Rodrigues AD ed) pp 231-358, Marcel Deckker, Inc., New York.
24. Pillot T, Ouzzine M, Fournel-Gigleux S, Lafaurie C, Radominska A, Burchell B, Siest G, and Magdalou J (1993) Glucuronidation of hyodeoxycholic acid in human liver. Evidence for a selective role of UDP- glucuronosyltransferase 2B4. J Biol Chem 268:25636-25642.
25. Rowland A, Gaganis P, Elliot DJ, Mackenzie PI, Knights KM, and Miners JO (2007) Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J Pharmacol Exp Ther 321:137-147.
26. Suhrland LG and Weisberger AS (1963) Chloramphenicol toxicity in liver renal disease. Arch Intern Med 112:747-754.
27. Tsoutsikos P, Miners JO, Stapleton A, Thomas A, Sallustio BC, and Knights KM (2004) Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. Biochem Pharmacol 67:191-199.
28. Uchaipichat V, Galetin A, Houston JB, Mackenzie PI, Williams JA, and Miners JO (2008) Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by UDP-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. Mol Pharmacol 74:1152-1162.
29. Venkatakrishnan K, Von Moltke LL, and Greenblatt DJ (2001) Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol 41:1149-1179.
30. Weiss CF, Glazko AJ, and Weston JK (1960) Chloramphenicol in the newborn infant. A physiologic explanation of its toxicity when given in excessive doses. N Engl J Med 262: 787-794.
31. Weiss JN (1997) The Hill equation revisited: uses and misuses. FASEB J11:835-841.
32. Yamanaka H, Nakajima M, Katoh M, Kanoh A, Tamura O, Ishibashi H, and Yokoi T (2005) Trans-3′-hydroxycotinine O- and N-glucuronidations in human liver microsomes. Drug Metab Dispos 33:23-30.